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A problem with rapid Plasmodium falciparum-specific antigen histidine-rich protein 2 (HRP2) detection tests
for malaria is the persistence of antigen in blood after the disappearance of asexual-stage parasitemia and
clinical symptoms, resulting in false-positive (FP) test results following treatment. The ICT P.f/P.v immuno-
chromatographic test detects both HRP2 and a panmalarial antigen (PMA) found in both P. falciparum and
Plasmodium vivax. To examine posttreatment antigen persistence with this test and whether persistent sexual-
stage forms (gametocytes) are a cause of FP tests after treatment, we compared serial antigen test results with
microscopy results from patients symptomatic with P. falciparum malaria in Indonesia for 28 days following
treatment with chloroquine (CQ; n 5 66), sulfadoxine-pyrimethamine (SP; n 5 36), and artesunate plus sulfa-
doxine-pyrimethamine (ART 1 SP; n 5 15). Persistent FP antigenemia following SP treatment occurred in 29%
(HRP2) and 42% (PMA) of the patients on day 7 and in 10% (HRP2) and 23% (PMA) on day 14. The high rates
of persistent HRP2 and PMA antigenemia following CQ and SP treatment were strongly associated with the
presence of gametocytemia, with the proportion with gametocytes on day 7 posttreatment being significantly
greater in those with FP results than in those with true-negative PMA and HRP2 results. Gametocyte frequency
on day 14 post-SP treatment was also greater in those with FP PMA results. Following SP treatment, PMA
persisted longer than HRP2, giving an FP diagnosis of P. vivax in up to 16% of patients on day 14, with all FP
P. vivax diagnoses having gametocytemia. In contrast, PMA was rapidly cleared following ART 1 SP treatment
in association with rapid clearance of gametocytemia. Gametocytes appear to be an important cause of per-
sistent posttreatment panmalarial antigenemia in areas of endemicity and may also contribute in part to per-
sistent HRP2 antigenemia following treatment.
Rapid dipstick antigen capture tests for the circulating Plas-
modium falciparum-specific antigen histidine-rich protein 2
(HRP2) have been shown to have excellent sensitivity and
specificity for the diagnosis of P. falciparum malaria, generally
at least as good as those for microscopy of a thick and thin film
by a skilled microscopist (25). Although currently too costly for
widespread use in countries where malaria is endemic, they
have become very useful as an adjunct or alternative to malaria
microscopy, particularly when experienced microscopists are
unavailable (24). A problem, however, when using these dip-
stick tests to detect asexual-stage falciparum parasitemia is the
persistence of HRP2 antigen in blood after the disappearance
of both asexual-stage parasitemia and clinical symptoms. This
may result in false-positive (FP) diagnoses of viable asexual
infection when HRP2 testing is performed after treatment of
malaria (24, 26) and may reduce the usefulness of the test in
predicting treatment failure (19, 21, 24).
Most published data on persistent HRP2 antigenemia after
treatment relate to the Parasight-F test for HRP2 (1, 2, 4, 9, 16,
21, 24, 25), which uses an immunoglobulin G (IgG) monoclo-
nal antibody to HRP2 in contrast to the IgM monoclonal
antibody to HRP2 used in the ICT Malaria P.f and ICT P.f/P.v
tests (11, 20). The ICT P.f/P.v test detects both the P. falcipa-
rum-specific antigen HRP2 and a panmalarial antigen (PMA)
found in both P. falciparum and Plasmodium vivax (20) but
possibly not in Plasmodium malariae (4a). An immunochro-
matographic diagnosis of P. falciparum is made if the HRP2
line is visible, with or without the PMA line. A diagnosis of
P. vivax is made if only the PMA line is visible (20). It is not
known how long the ICT P.f/P.v PMA persists after treatment
in areas where malaria is endemic. Antigen persistence after
treatment of P. falciparum with the ICT P.f/P.v test is impor-
tant not only because of the potential for convalescent FP
diagnoses and for potential inability to reliably predict treat-
ment failure but also because persistence of the antigen after
the HRP2 antigen has cleared would result in the test being
falsely interpreted as P. vivax. We therefore examined the
persistence of both the ICT P.f/P.v HRP2 and PMAs after
three different treatment regimens for P. falciparum malaria in
symptomatic Indonesians.
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Because it is not known to what extent gametocytes are de-
tected by either PMA or the IgM monoclonal antibody to HRP2,
an additional aim of the study was to determine whether per-
sistent antigenemia after treatment was associated with the
presence of sexual-stage forms (gametocytes) in convales-
cence. We examined the persistence of HRP2 and panmalarial
antigenemia following chloroquine treatment and sulfadoxine-
pyrimethamine treatment, both of which are associated with
high rates of posttreatment gametocytemia (6, 7, 8, 15). We
then examined the persistence of each antigen following treat-
ment with artesunate, which is associated with reduced game-
tocyte carriage in convalescence (12, 13).
MATERIALS AND METHODS
Study site. The studies examining persistence of antigenemia following chlo-
roquine and sulfadoxine-pyrimethamine were performed from February to May
1998 in Radamata Primary Health Centre, Laratama subdistrict, West Sumba,
East Nusa Tenggara province, Indonesia, an area where malaria is hypoendemic,
with a parasite rate in children aged 0 to 9 years of 5.1% (E. Tjitra, unpublished
data) and high rates of chloroquine resistance but no demonstrable sulfadoxine-
pyrimethamine resistance (18). The study examining clearance of antigenemia
following combination treatment with artesunate and sulfadoxine-pyrimeth-
amine was performed from March to April 1999 in Genyem Health Centre,
Nimboran subdistrict, Irian Jaya, Indonesia. This area has moderately high
malaria transmission, with parasite rates in children aged 0 to 9 years averaging
39% (Tjitra, unpublished) and high rates of resistance to chloroquine and doc-
umented sulfadoxine-pyrimethamine resistance (18). The studies were approved
by the Ethics Committee of the National Institute of Health Research and
Development, Indonesian Ministry of Health, Jakarta, Indonesia, and by the
Joint Institutional Ethics Committee of Menzies School of Health Research and
Royal Darwin Hospital, Darwin, Australia.
Patients and followup. The studies examining antigen clearance after chloro-
quine and sulfadoxine-pyrimethamine treatment were performed as part of 28-
day in vivo drug efficacy studies, using modified 1997 World Health Organization
guidelines with standard inclusion and exclusion criteria (18, 23). Sixty-six symp-
tomatic adults and children with a microscopic diagnosis of P. falciparum
monoinfection were enrolled. All patients were treated with a standardized
supervised 3-day regimen of oral chloroquine (Resochin; Bayer Pharmaceuticals,
Jakarta, Indonesia) at 10 mg of base/kg of body weight on days 1 and 2 and 5
mg/kg on day 3 without primaquine and were monitored with clinical review,
microscopy, and immunochromatographic testing on days 1, 2, 3, 7, 14, and 28.
Those with treatment failure with chloroquine but without danger signs (23)
requiring quinine treatment were then treated with sulfadoxine-pyrimethamine
(Fansidar; Roche, Jakarta, Indonesia) at 1.25 mg of pyrimethamine/kg and were
monitored for a further 28 days as described above.
The study examining antigen clearance after treatment with artesunate and
sulfadoxine-pyrimethamine was part of a pilot study examining combination
chemotherapy for malaria. Fifteen symptomatic adults and children with a mi-
croscopic diagnosis of P. falciparum monoinfection were treated with a standard-
ized supervised 3-day regimen of oral artesunate (Artesunate; Mekophar, Ho
Chi Minh City, Vietnam) at 4 mg/kg on days 1, 2, and 3 plus sulfadoxine-pyri-
methamine (Fansidar; Roche, Dee Why, New South Wales, Australia) at 1.25
mg/kg pyrimethamine on day 1. They were monitored for 28 days as described
above.
Microscopy and immunochromatographic testing. Thick and thin films were
examined and immunochromatographic testing was performed directly from
serial finger-prick blood samples collected on days 0, 1, 2, 3, 7, 14, and 28. Thick
and thin films were stained with 10% Giemsa solution and were examined at a
magnification of 31,000 by an expert microscopist with 24 years’ experience
(S. Suprianto) who was unaware of the clinical response to treatment or the im-
munochromatographic test results. Asexual- and sexual-stage parasite densities
were counted per 200 leukocytes and were then expressed in trophozoites per
microliter and gametocytes per microliter, assuming a leukocyte count of 8,000/
ml. Only those parasitemic with P. falciparum asexual stages (with or without
gametocytes) were eligible. Mixed infections with P. vivax were excluded. Thick
films were considered negative if no parasites were seen in at least 100 high-
power fields.
After a period of training, the ICT P.f/P.v test (AMRAD-ICT, Sydney, Aus-
tralia) was performed by clinic health workers using 15-ml finger-prick capillary
blood according to the manufacturer’s instructions and was read by the study
physician (E. Tjitra), who was blinded to microscopy results. The test was con-
sidered valid if the control line was visible and positive if the HRP2 and/or PMA
lines were visible. As per manufacturer’s instructions, an immunochromato-
graphic diagnosis of P. falciparum was made if the HRP2 line was visible, with or
without the PMA line. A diagnosis of P. vivax was made if only the PMA line was
visible. Coinfection with both P. falciparum and P. vivax cannot be distinguished
from infection with P. falciparum alone; the test interpretation of two visible lines
is P. falciparum.
All discordant slides and 20% of concordant slides were cross-checked by an
expert microscopist in Darwin with over 20 years’ experience, who was blinded to
patient diagnosis, previous microscopy, and immunochromatographic test re-
sults. A thick film was considered negative on cross-checking only if at least 200
high-power fields were negative. Results of microscopy and immunochromato-
graphic testing were compared following each drug on each of the follow-up
days.
Data analysis. Results were analyzed using Epi-Info version 6 (3). Because
gametocytes do not cause disease, immunochromatographic test results were
considered FP on each day of follow-up if positive for HRP2 or PMAs but
microscopically negative for asexual-stage parasites with or without gametocyte
positivity (25). Antigen test results were considered true negative if antigen
testing was negative and microscopy was negative for asexual-stage parasitemia,
with or without gametocyte positivity. To examine whether the presence of
gametocytes was associated with FP persistent antigenemia after treatment for
malaria, the proportion showing gametocytemia in those with true-negative an-
tigen test results was compared, using a two-tailed Fisher’s exact test, with the
proportion showing gametocytemia in those with FP antigen test results for each
antigen on days 7 and 14 after each treatment. Mean gametocyte counts in each
group were compared using the Mann-Whitney U test.
RESULTS
Microscopy findings following treatment. Sixty-six Sumba-
nese children and adults with symptomatic P. falciparum ma-
laria treated with chloroquine, 36 of the 37 recipients of failed
chloroquine treatment subsequently treated with sulfadoxine-
pyrimethamine, and all 15 patients treated with artesunate plus
sulfadoxine-pyrimethamine could be evaluated by both micros-
copy and immunochromatographic testing at least once. High
frequencies of recurrent asexual-stage P. falciparum parasi-
temia were found following treatment with chloroquine, but
there were no recurrences of asexual-stage P. falciparum par-
asitemia following sulfadoxine-pyrimethamine monotherapy
or treatment with a combination of artesunate and sulfadox-
ine-pyrimethamine (Fig. 1a). Over 50% of chloroquine-treated
patients who tested negative for asexual-stage parasites on
microscopy had P. falciparum gametocytemia on days 2, 3, 7,
and 14, with a similar proportion among patients who received
sulfadoxine-pyrimethamine (Fig. 1b). In contrast, as expected,
gametocytes occurred infrequently following artesunate com-
bination therapy and were cleared rapidly (Fig. 1b).
Antigen persistence following treatment. FP results with the
HRP2 and PMAs were found in 48% (32 of 66) and 41% (27
of 66) of patients, respectively, on at least 1 day of follow-up
following chloroquine, with each antigen found in 61% (22 of
36) of patients following sulfadoxine-pyrimethamine treatment
and in 100% (15 of 15) and 47% (7 of 15), respectively, fol-
lowing treatment with artesunate plus sulfadoxine-pyrimeth-
amine. Following chloroquine treatment, both total-positive
(Fig. 1c) and FP (Fig. 2a) HRP2 and panmalarial antigenemia
were more frequent and persisted longer than total positives
(Fig. 1d) and FPs (Fig. 2b) following sulfadoxine-pyrimeth-
amine treatment. Following sulfadoxine-pyrimethamine treat-
ment, a higher proportion of patients was FP for PMA than for
HRP2 antigen on each day of follow-up to day 14 (Fig. 2b).
Because PMA positivity in the absence of HRP2 positivity
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results in a diagnosis of P. vivax malaria, this caused a false-
convalescent immunochromatographic diagnosis of vivax ma-
laria on days 1, 2, 3, 7, and 14 in 1 (3%), 2 (9%), 3 (10.3%), 4
(12.9%), and 5 (16.1%) evaluable patients, respectively. Sig-
nificantly, in all of these 15 FP diagnoses of vivax malaria,
P. falciparum gametocytes were present on microscopy. Fol-
lowing chloroquine treatment, a FP diagnosis of P. vivax oc-
curred on day 7 only and was made in 2 of 24 (8%) patients
negative for P. falciparum asexual-stage parasites on micros-
copy.
In contrast to the findings following treatment with chloro-
quine and sulfadoxine-pyrimethamine, therapy with artesunate
plus sulfadoxine-pyrimethamine was followed by high frequen-
cies of persistent HRP2 antigenemia but rapid clearance of
panmalarial antigenemia (Fig. 2c), which paralleled the rapid
clearance of gametocytemia. There were no FP diagnoses of
P. vivax in convalescence. There was a recrudescence of pan-
malarial antigenemia on day 28 in the absence of asexual-stage
or sexual-stage parasites on microscopy, which may have re-
flected emerging subpatent reinfection in this area of moder-
ately high transmission in Irian Jaya.
Relationship between gametocytes and antigen persistence
following treatment. On each day of follow-up after both chlo-
roquine (Fig. 3a) and sulfadoxine-pyrimethamine (Fig. 3b), the
majority of FP results for both HRP2 and PMAs were associ-
ated with gametocytemia, whereas gametocytemia was found
in only a minority of true-negative antigen results. On day 7
posttreatment, the proportion with gametocytes was signifi-
cantly greater among those with FP HRP2 tests than among
those with true-negative results: 11 of 14 versus 3 of 10 (P 5
0.035) after chloroquine treatment and 9 of 9 versus 8 of 21
(P 5 0.001) after sulfadoxine-pyrimethamine treatment. With
fewer HRP2 FPs by day 14, the difference between the pro-
portion with gametocytes in those with FP HRP2 results and
that in those with true-negative results was no longer statisti-
cally significant on day 14. The association between PMA false
positivity and gametocytemia was even stronger. On day 7
posttreatment, the proportion with gametocytes was signifi-
cantly greater among those with FP PMA results than among
those with true-negative results: 11 of 12 versus 3 of 12 (P 5
0.0009) after chloroquine treatment and 13 of 13 versus 4 of 17
(P 5 0.0001) after sulfadoxine-pyrimethamine treatment. On
day 14, gametocyte frequency was also greater in patients with
FP PMA results than in those with true-negative results fol-
lowing sulfadoxine-pyrimethamine treatment: 6 of 7 versus 9 of
24 (P 5 0.02).
FIG. 1. Microscopic findings (a and b) following chloroquine treatment of P. falciparum malaria, sulfadoxine-pyrimethamine treatment of
patients who had received failed chloroquine treatment, and treatment with artesunate plus sulfadoxine-pyrimethamine. (a) Recurrence of asexual
P. falciparum parasitemia following chloroquine treatment is shown. p, P. vivax asexual parasitemia was noted on day 28 in one sulfadoxine-py-
rimethamine-treated patient and in two patients following treatment with artesunate plus sulfadoxine-pyrimethamine. (b) Proportion with P.
falciparum gametocytemia in those negative for asexual-stage P. falciparum parasites on each day of follow-up. (c) Antigen persistence following
chloroquine treatment. The proportion of all patients having HRP2 or panmalarial antigenemia on each day of follow-up is shown. (d) Antigen
persistence following sulfadoxine-pyrimethamine treatment. The proportion of all patients having HRP2 or panmalarial antigenemia on each day
of follow-up is shown.
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In marked contrast to the findings following chloroquine and
sulfadoxine-pyrimethamine treatment, there were no FP PMA
results following treatment with artesunate plus sulfadoxine-
pyrimethamine (Fig. 3c). Importantly, this lack of convales-
cent-stage FP PMA results was strongly associated with lack of
gametocytemia, with gametocytes being present at very low
levels (mean, 120/ml) in only 2 of 15 patients (13%) on day 7
and absent in all patients on day 14. Conversely, a high pro-
portion of those with FP HRP2 antigen tests following therapy
with artesunate plus sulfadoxine-pyrimethamine did not have
gametocytemia, suggesting that other causes of persistent
HRP2 antigenemia are important in this high-transmission set-
ting.
Although a greater proportion of those with FP antigen tests
following both chloroquine and sulfadoxine-pyrimethamine
treatment had gametocytemia, gametocytes were also found in
those with true-negative antigen tests. Comparison of mean
gametocyte counts indicated that those with FP antigen tests
had higher mean gametocyte counts than did those with true-
negative tests (Table 1), particularly following sulfadoxine-py-
rimethamine treatment. This was a consistent trend which,
despite small numbers, reached statistical significance for
PMA. Although the numbers were small, there was a trend for
mean gametocyte counts to be higher in patients with true-
negative convalescent-stage HRP2 antigen test results than in
those with true-negative PMA test results, suggesting a poten-
tially higher gametocyte detection threshold for HRP2. When
day-0 asexual-stage parasite counts in those with convalescent-
stage FP antigen tests were compared with counts for those
with true-negative results, there were no consistent differences.
DISCUSSION
We have demonstrated high rates of persistent positive re-
sults for both antigens with the ICT P.f/P.v test after treatment
of symptomatic Indonesians with P. falciparum malaria using
the two most commonly used antimalarial drugs worldwide,
chloroquine and sulfadoxine-pyrimethamine. There are several
lines of evidence to suggest that persistence of PMA following
clearance of asexual-stage parasites in residents of areas of
malaria endemicity results largely from detection of circulating
sexual stages in convalescence. In this study we found a con-
sistent association between gametocytemia and FP panmalarial
antigenemia on days 7 and 14 following treatment with both
chloroquine and sulfadoxine-pyrimethamine. Moreover, game-
tocyte density was higher in those with convalescent-stage
PMA false positivity than in those with true-negative results,
consistent with gametocyte density being above the antigen
detection threshold in those with FP tests. Thirdly, and in
marked contrast to the findings following chloroquine and
sulfadoxine-pyrimethamine treatment, artesunate therapy re-
sulted in rapid clearance of gametocytes which was associated
with a rapid clearance of panmalarial antigenemia and in an
absence of FP results by day 7. This last finding is consistent
with results from a recent hospital series (in an area where
malaria is not endemic) of eight cases with P. falciparum mon-
itored longitudinally with the ICT P.f/P.v test after treatment
with an unnamed drug(s) (5). In these patients, PMA reactivity
declined in parallel with the decline in parasitemia, with no FP
PMA results in convalescence. Significantly, these patients
were treated early and none developed gametocytemia, further
evidence that detection of gametocytes is the predominant
cause of the convalescent-stage FP panmalarial antigenemia
found in endemic areas.
Potential alternative causes of persistent panmalarial anti-
genemia early in convalescence are unlikely to have contrib-
FIG. 2. FP persistence of HRP2 and panmalarial antigenemia fol-
lowing treatment with chloroquine (a), sulfadoxine-pyrimethamine
(b), and artesunate plus sulfadoxine-pyrimethamine (c) of symptom-
atic P. falciparum malaria. Results do not include true-positive results
associated with asexual-stage parasitemia on microscopy and are ex-
pressed as FP antigen results, as a proportion of the total FP and
true-negative results for each antigen on each day of follow-up.
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uted to a major degree to the day-7 and -14 FP results that we
observed. While it could be argued that in an area of known
chloroquine resistance, persistent asexual-stage parasitemia
below the threshold for microscopic detection could poten-
tially result in persistent true-positive panmalarial antigenemia
following chloroquine treatment and could also, as an epiphe-
nomenon, result in posttreatment gametocytemia (7), this would
not explain the persistent panmalarial antigenemia following
sulfadoxine-pyrimethamine treatment (and its association with
gametocytemia), in which there were no parasitological or clin-
ical failures observed in 28 days of follow-up. Conversely, late
recurrence of panmalarial antigenemia following initial clear-
ance, as we found following therapy with artesunate plus sul-
fadoxine-pyrimethamine, is consistent with emerging reinfec-
tion in this high-transmission region (Tjitra, unpublished) at a
level below the detection limit for microscopy.
Antigen persistence after treatment of P. falciparum with the
ICT P.f/P.v test is important not only because of the potential
for FP diagnosis of asexual-stage infection in convalescence
but also because the persistence of PMA after the HRP2 an-
tigen has cleared, as we observed following chloroquine ther-
apy and particularly sulfadoxine-pyrimethamine therapy, re-
sults in the test being falsely interpreted as positive for P. vivax.
This is likely to be a particular problem in semiimmune resi-
dents of areas of malaria endemicity, where greater chronicity
of infection prior to treatment results in higher frequencies of
gametocytemia on presentation (6) and where previous self-
treatment is common. Moreover, treatment of chloroquine-
resistant P. falciparum with chloroquine, as is widely practiced
in areas of malaria endemicity, results in higher frequencies of
gametocytemia in convalescence than following treatment of
chloroquine-sensitive strains (7, 14). Rates of gametocytemia
in areas of endemicity where chloroquine is still used are now
much higher than those noted before chloroquine resistance
emerged (7). However, because gametocyte carriage is mark-
edly reduced following artesunate therapy (12), persistent FP
panmalarial antigenemia is unlikely to be a major problem in
areas of malaria endemicity, such as Thailand and Vietnam,
which have switched to artesunate-containing combination
therapies (12). Because posttreatment gametocytemia is also
unusual in nonimmune returned travelers owing to the usually
shorter duration of infection prior to treatment, convalescent-
FIG. 3. Frequency of P. falciparum gametocytemia on days 7 and
14 after treatment with chloroquine (a), sulfadoxine-pyrimethamine
(b), and artesunate plus sulfadoxine-pyrimethamine (c) in those with
FP immunochromatographic antigen tests (below the zero line) com-
pared with those with true negative tests (above the zero line). p in-
dicates a significant difference (P , 0.05) using Fisher’s two-tailed
exact test.
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stage panmalarial antigenemia is also unlikely to be a problem
in these patients (5). Testing for PMA after treatment may
therefore prove to be potentially useful only in predicting treat-
ment failure in those settings, as described above, where post-
treatment gametocytemia is uncommon.
The cause of persistent HRP2 antigenemia after malaria
treatment is not known. Potential causes include persistent
viable asexual-stage parasitemia below the detection limit of
microscopy, delayed clearance of circulating antigen (free or in
antigen-antibody complexes), rheumatoid factor, and persis-
tent sexual-stage forms (gametocytes) (24, 25; M. P. Grobusch,
U. Alpermann, S. Schwenke, T. Jelinek, and D. C. Warhurst,
Letter, Lancet 353:297). It is still not clear to what extent
HRP2 is found in gametocytes. While HRP2 has been de-
scribed in published reviews as being found in immature
but not mature gametocytes (25), to date there are no pub-
lished primary data supporting this assertion. Recently, HRP2
mRNA transcript and protein have both been demonstrated in
late-stage gametocytes (R. Haywood, D. Sullivan, and K. Day,
personal communication). An early study with Kenyan chil-
dren found no association between posttreatment gameto-
cytemia and Parasight-F HRP2 false positivity 6 days after
treatment (2), but until now this association has not been specif-
ically looked for in convalescence since. We have demonstrated
an association between circulating gametocytemia and persis-
tent ICT P.f/P.v. HRP2 antigen reactivity following both chlo-
roquine and sulfadoxine-pyrimethamine treatments, suggest-
ing that detection of gametocytes may contribute to persistent
FP HRP2 reactivity in convalescence. Importantly, the lack of
demonstrable sulfadoxine-pyrimethamine resistance at the
Sumba study site (18) makes it unlikely that the association
between FP HRP2 antigen reactivity and gametocytemia fol-
lowing sulfadoxine-pyrimethamine treatment is related to an
epiphenomenon of persistent submicroscopic asexual-stage
parasitemia causing both persistent HRP2 and gametocytemia.
An Indian study also found a high frequency of persistent ICT
P.f. HRP2 antigen following treatment with sulfadoxine-pyri-
methamine (42% on day 7), with half of these FP HRP2 results
on day 7 being gametocytemic, but rates of gametocytemia in
those with true-negative results on day 7 were not reported
(17). In cross-sectional evaluations of the Parasight-F (10) and
ICT P.f/P.v immunochromatographic tests (20), the sensitivity
of the HRP2 antigen for gametocytes in those negative for
asexual stages was 22 and 73%, respectively. It is possible that
there are differences between the ability of the IgG monoclo-
nal antibody to HRP2 used in the Parasight-F test to detect
gametocytes and that of the IgM monoclonal antibody to
HRP2 used in the ICT Malaria P.f and ICT P.f/P.v tests, how-
ever, proving this theory will require direct comparative stud-
ies.
While we found an association between gametocytemia and
HRP2 antigen reactivity following treatment, we and others
have also found evidence that other causes of persistent HRP2
are important. Indeed, in contrast to PMA reactivity, other
causes of persistent HRP2 reactivity are likely to be more
important than posttreatment gametocytemia. We found high
frequencies of persistent HRP2 reactivity following artesunate
combination therapy, despite the rapid clearance of gameto-
cytemia. Persistent ICT P.f/P.v HRP2 reactivity to day 31 has
also been reported in a patient without patent gametocytemia
(5). We found higher rates of FP HRP2 antigenemia following
chloroquine treatment than following sulfadoxine-pyrimeth-
amine therapy, despite similar frequencies of posttreatment
gametocytemia and despite the drugs sharing similar rates of
asexual-stage parasite clearance when parasites are drug sen-
sitive (22). This may relate to chloroquine resistance but not
sulfadoxine-pyrimethamine resistance being found at the study
site and suggests that subclinical drug-resistant asexual-stage
parasitemia below the detection limit of microscopy may con-
tribute to the higher frequency of persistence following chlo-
roquine (19).
The gametocyte detection threshold for HRP2 may be
higher than that for PMA. All of the convalescent FP diag-
noses of P. vivax (i.e., HRP2 negative and PMA positive) had
gametocytes. In the presence of declining gametocyte levels
following sulfadoxine-pyrimethamine treatment, HRP2 reac-
tivity fell more quickly than PMA reactivity, with a trend of
higher gametocyte counts in those with true-negative conva-
lescent HRP2 reactivity than in those with true-negative PMA
reactivity.
In conclusion, it is likely that gametocytes are the predom-
inant cause of persistent PMA reactivity after treatment of
malaria. Persistent PMA reactivity in convalescence does not
appear to occur in those patients who do not develop game-
TABLE 1. Gametocyte density in patients with FP panmalarial and HRP2 antigenemia after treatment compared
to that in those with true-negative antigen resultsa
Antigen Drug used Day aftertreatment
Results for FPs Results for true negatives
P
n
Gametocyte densityb
n
Gametocyte density
Mean (SEM) Mean (SEM)
PMA Chloroquine 7 11 768 (212) 3 80 (0) 0.07
14 7 263 (92) 7 114 (44) 0.24
Sulfadoxine-pyrimethamine 7 13 712 (176) 4 130 (41) 0.008
14 6 280 (92) 9 80 (16) 0.006
HRP2 Chloroquine 7 11 652 (212) 3 508 (428) 0.64
14 7 263 (92) 7 114 (44) 0.24
Sulfadoxine-pyrimethamine 7 9 812 (246) 8 310 (100) 0.07
14 2 120 (80) 13 168 (48) 0.80
a Mean gametocyte counts in each group are compared using the Mann-Whitney U test.
b Density is given as gametocytes per microliter.
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tocytes following treatment and is unlikely to be a diagnostic
problem in these patients. In contrast, because gametocyte-
associated PMA reactivity persists longer than HRP2 reactivity
after treatment, a high percentage of those with posttreatment
gametocytemia have FP ICT P.f/P.v diagnoses of P. vivax in
convalescence. While gametocytes are associated with, and
likely contribute to, persistent ICT P.f/P.v HRP2 antigen re-
activity after chloroquine and sulfadoxine-pyrimethamine
treatment of P. falciparum malaria, other factors are likely to
be more important causes of the FP HRP2 reactivity seen in
convalescence.
ACKNOWLEDGMENTS
We thank Mary Dyer for expert cross-checking of malaria micros-
copy; Mary Garcia of AMRAD-ICT for providing the ICT P.f/P.v tests;
Ken Ilett for assistance with supply of the artesunate; Umar Fahmi
Achmadi, Sumarjati Arjoso, Harijani Marwoto, Thomas Suroso, and
Ferdinand Laihad of the Ministry of Health, Jakarta, Indonesia, for
their support; Elizabeth Stubbs for logistic help; Bambang Purnomo,
Budi Subianto, Tony Dimpudus, Ingko Gunawan, Krisman Hutadjulu,
Ester Ayomi, Agus Berek, Frankie Hartanto, Sunarno, Frans Pello,
Markus, Wayan, Yulius Weng, Gede Utomo, Neli, and their staff; and
the Regional, Provincial, District, and Subdistrict Health Offices of
East Nusa Tenggara and Irian Jaya, Indonesia, for support and tech-
nical assistance.
We are grateful for Northern Territory Government 50th Anniver-
sary of Indonesian Independence Malaria-Tuberculosis Research Fel-
lowships and to Mark Nicholson and Alice Hill, who assisted in meet-
ing the costs of the artesunate studies. The expense of the ICT P.f/
P.v kits and some logistical costs for the Sumba studies were under-
written by AMRAD-ICT, Sydney, New South Wales, Australia.
REFERENCES
1. Banchongaksorn, T., P. Yomokgul, S. Panyim, W. Rooney, and P. Vickers.
1996. A field trial of the ParaSight-F test for the diagnosis of Plasmodium
falciparum infection. Trans. R. Soc. Trop. Med. Hyg. 90:244–245.
2. Beadle, C., G. Long, W. Weiss, P. McElroy, S. Maret, A. Oloo, and S. Hoff-
man. 1994. Diagnosis of malaria by detection of Plasmodium falciparum
HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet 343:564–
568.
3. Dean, A. G., J. A. Dean, D. Coulombier, K. A. Brendel, D. C. Smith, A. H.
Burton, R. C. Dicker, K. Sullivan, R. F. Fagan, and T. G. Arner. 1995. Epi
Info, version 6: a word-processing database and statistics program for public
health on IBM-compatible microcomputers. Centers for Disease Control
and Prevention, Atlanta, Ga.
4. Di Perri, G., P. Olliaro, S. Nardi, B. Allegranzi, R. Deganello, S. Vento, M.
Lanzafame, A. Cazzadori, S. Bonora, and E. Concia. 1997. The ParaSight-F
rapid dipstick antigen capture assay for monitoring parasite clearance after
drug treatment of Plasmodium falciparum malaria. Trans. R. Soc. Trop.
Med. Hyg. 91:403–405.
4a.Dyer, M. E., E. Tjitra, B. J. Currie, and N. M. Anstey. 2000. Failure of the
‘pan-malarial’ antibody of the ICT Malaria P.f/P.v immunochromatographic
test to detect symptomatic Plasmodium malariae infection. Trans. R. Soc.
Trop. Med. Hyg. 94:518.
5. Eisen, D., and A. Saul. 2000. Disappearance of pan-malarial antigen reac-
tivity using the ICT Malaria P.f/P.v kit parallels decline of patent parasitae-
mia as shown by microscopy. Trans. R. Soc. Trop. Med. Hyg. 94:169–170.
6. Field, J., and P. Shute. 1956. The microscopic diagnosis of human malaria,
vol. 2. A morphological study of the erythrocytic parasites. Institute for
Medical Research, Kuala Lumpur, Malaysia.
7. Handunetti, S., D. Gunawardena, P. Pathirana, K. Ekanayake, S. Weera-
singhe, and K. Mendis. 1996. Features of recrudescent chloroquine-resistant
Plasmodium falciparum infections confer a survival advantage on parasites
and have implications for disease control. Trans. R. Soc. Trop. Med. Hyg.
90:563–567.
8. Hogh, B., A. Gamage-Mendis, G. A. Butcher, R. Thompson, K. Begtrup, C.
Mendis, S. M. Enosse, M. Dgedge, J. Barreto, W. Eling, and R. E. Sinden.
1998. The differing impact of chloroquine and pyrimethamine/sulfadoxine
upon the infectivity of malaria species to the mosquito vector. Am. J. Trop.
Med. Hyg. 58:176–182.
9. Karbwang, J., O. Tasanor, T. Kanda, Y. Wattanagoon, M. Ibrahim, K.
Na-Bangchang, A. Thanavibul, and W. Rooney. 1996. ParaSight-F test for
the detection of treatment failure in multidrug resistant Plasmodium falci-
parum malaria. Trans. R. Soc. Trop. Med. Hyg. 90:513–515.
10. Kodisinghe, H. M., K. L. Perera, S. Premawansa, T. Naotunne, A. R. Wick-
ramasinghe, and K. N. Mendis. 1997. ParaSight-F dipstick test as a routine
diagnostic tool for malaria in Sri Lanka. Trans. R. Soc. Trop. Med. Hyg.
91:398–402.
11. Makler, M. T., C. J. Palmer, and A. L. Ager. 1998. A review of practical
techniques for the diagnosis of malaria. Ann. Trop. Med. Parasitol. 92:419–
433.
12. Price, R., F. Nosten, C. Luxemberger, F. ter Kuile, L. Paiphun, T. Chong-
suphajaisiddhi, and N. White. 1996. Effects of artemisinin derivatives on
malaria transmissibility. Lancet 347:1654–1658.
13. Price, R., F. Nosten, J. A. Simpson, C. Luxemburger, L. Phaipun, F. ter
Kuile, M. van Vugt, T. Chongsuphajaisiddhi, and N. J. White. 1999. Risk
factors for gametocyte carriage in uncomplicated falciparum malaria. Am. J.
Trop. Med. Hyg. 60:1019–1023.
14. Robert, V., H. P. Awono-Ambene, J. Y. Le Hesran, and J. F. Trape. 2000.
Gametocytemia and infectivity to mosquitoes of patients with uncomplicated
Plasmodium falciparum malaria attacks treated with chloroquine or sulfa-
doxine plus pyrimethamine. Am. J. Trop. Med. Hyg. 62:210–216.
15. Robert, V., J. F. Molez, and J. F. Trape. 1996. Short report: gametocytes,
chloroquine pressure, and the relative parasite survival advantage of resis-
tant strains of falciparum malaria in west Africa. Am. J. Trop. Med. Hyg.
55:350–351.
16. Shiff, C. J., Z. Premji, and J. N. Minjas. 1993. The rapid manual ParaSight-F
test. A new diagnostic tool for Plasmodium falciparum infection. Trans. R.
Soc. Trop. Med. Hyg. 87:646–648.
17. Singh, N., N. Valecha, and V. P. Sharma. 1997. Malaria diagnosis by field
workers using an immunochromatographic test. Trans. R. Soc. Trop. Med.
Hyg. 91:396–397.
18. Tjitra, E., S. Suprianto, M. Dyer, B. Currie, and N. Anstey. 1999. Evaluation
of the therapeutic efficacy of chloroquine and sulfadoxine-pyrimethamine in
uncomplicated falciparum malaria in Eastern Indonesia: high rates of chlo-
roquine treatment failure with poor hematological recovery. Am. J. Trop.
Med. Hyg. 61(Suppl.):S286–S287. (Abstract.)
19. Tjitra, E., S. Suprianto, M. Dyer, B. Currie, and N. Anstey. 1999. Utility of
the ICT Malaria P.f/P.v immunochromatographic test in diagnosing/predict-
ing treatment outcome following treatment of uncomplicated falciparum
malaria in Eastern Indonesia. Am. J. Trop. Med. Hyg. 61(Suppl.):S472.
20. Tjitra, E., S. Suprianto, M. Dyer, B. J. Currie, and N. M. Anstey. 1999. Field
evaluation of the ICT Malaria P.f/P.v immunochromatographic test for de-
tection of Plasmodium falciparum and Plasmodium vivax in patients with a
presumptive clinical diagnosis of malaria in eastern Indonesia. J. Clin. Mi-
crobiol. 37:2412–2417.
21. Vakharia, S., N. Gopinathan, and N. A. Kshirsagar. 1997. The ParaSight-F
test for detecting treatment failure. Trans. R. Soc. Trop. Med. Hyg. 91:490–
491.
22. Warrell, D. 1993. Treatment and prevention of malaria, p. 164–195. In H.
Gilles and D. Warrell (ed.), Essential malariology, 3rd ed. Edward Arnold,
London, United Kingdom.
23. World Health Organization. 1997. Assessment of therapeutic efficacy of
antimalarial drugs for uncomplicated falciparum malaria. Division of Con-
trol of Tropical Diseases, World Health Organization, Geneva, Switzerland.
24. World Health Organization. 2000. New perspectives malaria diagnosis.
World Health Organization, Geneva, Switzerland.
25. World Health Organization. 1996. A rapid dipstick antigen capture assay for
the diagnosis of falciparum malaria. WHO informal consultation on recent
advances in diagnostic techniques and vaccines for malaria. Bull. W. H. O.
74:47–54.
VOL. 39, 2001 PERSISTENT ICT P.f/P.v ANTIGENEMIA AFTER TREATMENT 1031
